A securities class action has been filed against Inovio Pharmaceuticals Inc., alleging the company made false or misleading statements during the period from Oct. 10, 2023, to Dec. 26, 2025. The suit claims Inovio failed to disclose deficiencies in manufacturing for its CELLECTRA device and overstated the regulatory and commercial prospects for INO-3107, including expectations around the timing and viability of a Biologics License Application and potential for accelerated approval or priority review. An April 7, 2026 deadline has been set for investors seeking to be appointed lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602220933PRIMZONEFULLFEED9658476) on February 22, 2026, and is solely responsible for the information contained therein.